Diet Impact on Insulin Resistance
Trial Summary
What is the purpose of this trial?
Advancing age is associated with gut dysbiosis, low-grade chronic inflammation, progressive insulin resistance, and increased risk of type 2 diabetes (T2D). Prediabetes is present in 45-50% of middle-aged/older adults, and declines in glucose tolerance are evident in the third or fourth decade of life. Thus, there is an urgent need to identify new approaches for the prevention of type 2 diabetes among middle-aged adults. Observational research has linked intake of ultra-processed foods (UPF), which comprise \~60% of total energy intake in US adults, with increased risk of T2D. Ex vivo and animal research suggests that components of UPF alter gut microbiota composition and initiate a cascade of events leading to intestinal inflammation and impaired glycemic control. Whether mid-life adults (aged 45-65 yrs) are susceptible to the adverse impact of UPF consumption on glucose homeostasis is unknown. The overall objective of this study is to establish proof-of-concept for an impairment in glucose homeostasis following increases in UPF consumption in mid-life adults, in order to conduct a larger, more comprehensive and mechanistic trial in the future. In addition, changes in gut microbial composition and function, intestinal inflammation and permeability, serum endotoxin concentrations, and inflammatory cytokines as potential mechanisms by which UPF consumption influences glucose homeostasis will be investigated.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, if you are on stable doses of estrogen, testosterone, or antihypertensive medications for more than 6 months, you can continue taking them.
What data supports the effectiveness of the treatment for improving insulin resistance?
Research suggests that diets high in unsaturated fatty acids (like those found in some whole and minimally processed foods) are linked to better insulin resistance. Additionally, diets low in saturated fats and high in fiber, which are characteristics of whole and minimally processed foods, are associated with improved insulin sensitivity.12345
Is the diet impact on insulin resistance treatment generally safe for humans?
Research indicates that high consumption of ultra-processed foods (UPF) is linked to various health risks, including obesity, type 2 diabetes, cardiovascular diseases, and increased mortality. Conversely, diets low in UPF, such as whole food or minimally processed food diets, are generally considered safer and healthier for humans.678910
How does the High UPF controlled diet treatment differ from other treatments for insulin resistance?
The High UPF controlled diet is unique because it focuses on the impact of ultra-processed foods, which are often high in saturated fats and low in fiber, on insulin resistance. Unlike other dietary approaches that emphasize specific nutrient modifications, this treatment examines the broader effects of processed food consumption on insulin sensitivity.12111213
Research Team
Brenda M Davy, PhD, RD
Principal Investigator
Virginia Polytechnic Institute and State University
Eligibility Criteria
This trial is for middle-aged adults (45-65 years old) who are sedentary to moderately active, not planning to change their weight or activity level, and can commit to an 8-week study with daily food pickups. They must be stable in terms of medication for hormones and blood pressure if applicable, and not have a history of significant health issues like heart disease or diabetes.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants consume a diet containing either 81% or 0% total energy from ultra-processed foods for 6 weeks
Follow-up
Participants are monitored for changes in insulin sensitivity, glucose control, and other health markers after the diet intervention
Treatment Details
Interventions
- High UPF controlled diet
- No UPF controlled diet
Find a Clinic Near You
Who Is Running the Clinical Trial?
Virginia Polytechnic Institute and State University
Lead Sponsor
Duke University
Collaborator